Steroids Can Be Stopped in Some Older Myeloma Patients Steroids Can Be Stopped in Some Older Myeloma Patients
In intermediate-fit elderly patients newly diagnosed with multiple myeloma, dexamethasone can be stopped during maintenance without having an adverse effect on outcome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news
Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news
Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news
New figures show dexamethasone treatment for COVID-19 has so far saved 22,000 lives in UK, NHS England (published 23rd March 2021)
These figures were released by NHS England, who noted dexamethasone has also saved ~1 million lives worldwide since the positive findings from RECOVERY trial of decreased risk of death by a third in patients on ventilators and by almost a fifth in those on oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 24, 2021 Category: Consumer Health News Source Type: news
COVID treatment developed in the NHS saves a million lives
Dexamethasone, an inexpensive and widely available steroid, has saved around one million lives worldwide since its discovery as an effective treatment for COVID-19 in a clinical trial in the NHS. (Source: NHS Networks)
Source: NHS Networks - March 23, 2021 Category: UK Health Source Type: news
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both monthly dosing an...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a stable regimen,...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
DEX Blunts Postspinal Hypotension in Geriatric Patients DEX Blunts Postspinal Hypotension in Geriatric Patients
Might dexamethasone be effective in in preventing or decreasing the incidence of post-spinal anesthesia hypotension in elderly patients?BMC Anesthesiology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 24, 2021 Category: Orthopaedics Tags: Anesthesiology Journal Article Source Type: news
UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news
COVID-19 Pandemic has Shown Humanity at its Best – & at its Worst
A health worker at a local health centre in Kinshasa, Democratic Republic of the Congo, prepares a vaccine injection. The dispatch of millions of COVID-19 vaccines to Africa started in February. Credit: UNICEF/Sibylle DesjardinsBy Tedros Adhanom GhebreyesusGENEVA, Feb 11 2021 (IPS) WHO and UNICEF have a long, deep and very special relationship. Neither of us could do what we do without the other.
UNICEF’s success is WHO’s success, and we are proud to be your partner on so many issues: Ebola, polio, maternal health, nutrition, infection prevention and control, primary health care – the list is long.
Never has our pa...
Source: IPS Inter Press Service - Health - February 11, 2021 Category: International Medicine & Public Health Authors: Tedros Adhanom Ghebreyesus Tags: Development & Aid Education Global Globalisation Headlines Health Inequity Poverty & SDGs TerraViva United Nations Source Type: news
Oral Mosapride as Anti-emetic Following General Anesthesia Oral Mosapride as Anti-emetic Following General Anesthesia
Might the addition of prophylactic oral mosapride to a protocol including dexamethasone and ondansetron further reduce postoperative nausea and vomiting after general anesthesia?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 2, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves First and Only Treatment for AL Amyloidosis FDA Approves First and Only Treatment for AL Amyloidosis
Accelerated approval has been granted to daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone for treatment of newly diagnosed light chain amyloidosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
